Compare Amgen, Inc. (AMGN) vs Caesars Entertainment Inc (CZR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Caesars Entertainment Inc — how do they compare? Amgen, Inc. trades at $363.26 (market cap $196.12B), while Caesars Entertainment Inc trades at $29.86 (market cap $6.08B). The key difference: Amgen, Inc. is far larger — about 32.3× Caesars Entertainment Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Caesars Entertainment Inc pays none. Which is the better fit depends on your goals.
| AMGN | CZR | |
|---|---|---|
Market Cap | $196.12B | $6.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $30.84 |
52-Week Low | $271.18 | $18.14 |
Enterprise Value | $241.41B | $30.14B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CZR trades at $29.84, up 0.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $31.27. The company reported Q1 2026 EPS of -$0.48, missing expectations, and has a negative net income margin of -4.19%. Recent news highlights the pending acquisition by Fertitta Entertainment and the opening of Caesars Republic Lake Tahoe.
CZR faces headwinds from recent earnings misses and negative profitability, but the acquisition offer and improving cash flow trends provide upside potential. Risks include high debt levels and competitive pressures in the leisure sector. Analyst sentiment is mixed with 33% buy ratings, suggesting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →
